In patients with hypertension, psoriasis linked to increased risk for cardiovascular procedures, surgeries.
DLQI-R allows more patients to achieve threshold for becoming candidates for biologic treatment.
Psoriasis appears to be significantly associated with inflammatory bowel disease.
Most studies evaluated fish oil, acupuncture, indigo naturalis, curcumin, meditation.
The final analysis set comprised biologic-naïve individuals — individuals who had filled an initial prescription for etanercept, infliximab, adalimumab, or ustekinumab after 2 years without using any biologic agent during the study period.
Some of the comorbidities include increased lipid levels, hypertension, and diabetes.
Medication-related adverse events occur more frequently with methotrexate in children with moderate to severe psoriasis.
Patients with psoriasis whose disease affects >10% of their body surface area (BSA) are at an increased risk for death compared with the general population.
Sleep complaints among individuals with psoriasis warrant greater clinical attention, as they have a greater chance for developing obstructive sleep apnea.
Patients with psoriasis have a greater risk of mortality due to alcohol-related causes, including alcoholic liver disease, fibrosis and cirrhosis of the liver, and mental and behavioral disorders.
This study shows that more than 50% of patients can expect a 90% or greater improvement in scalp psoriasis within 12 weeks.
Researchers observed a positive correlation between the amount and duration of smoking and the occurrence of psoriasis.
Biosimilar ABP 501 has similar clinical efficacy and safety to adalimumab for the treatment of plaque psoriasis.
Dalazatide treatment reduced the plasma levels of multiple inflammation markers and reduced the expression of T cell activation markers on peripheral blood memory T cells.
The guidelines are the first to provide recommendations for comorbidity screening in pediatric psoriasis patients.
The most common comorbidities found in patients with psoriasis are hyperlipidemia, hypertension, depression, type 2 diabetes mellitus, and obesity.
Researchers sought to analyze long-term and real-world outcome data in patients with moderate-to-severe psoriasis after starting biologic treatment.
Presence of psoriatic arthritis, weight, employment status, baseline disease severity affect the selection of first-line biologic treatment.
Nearly 50% of patients with psoriatic arthritis report elevated levels of fatigue.
The biosimilar has also been approved for Crohn’s disease, ulcerative colitis, and ankylosing spondylitis.